Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.47 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.47 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3771754 | 0.97 | GAA (0.48) | GAAHPGDL3MBTL3L3MBTL1GFER | |
| SCHEMBL3773816 | 0.89 | L3MBTL1 (0.51) | GAAHPGDL3MBTL3L3MBTL1ALDH1A1 | |
| SCHEMBL3769783 | 0.89 | L3MBTL3 (0.46) | L3MBTL3L3MBTL1GFERSMN1; SMN2MBTD1 | |
| SCHEMBL3771828 | 0.87 | L3MBTL3 (0.60) | L3MBTL3L3MBTL1GFERSMN1; SMN2MBTD1 | |
| SCHEMBL3780602 | 0.86 | HRH3 (0.49) | GAAHPGDL3MBTL3L3MBTL1HRH3 | |
| SCHEMBL3768075 | 0.86 | L3MBTL1 (0.49) | L3MBTL3L3MBTL1ALDH1A1MAPTLMNA | |
| SCHEMBL3767563 | 0.86 | L3MBTL3 (0.59) | L3MBTL3L3MBTL1GFERSMN1; SMN2MBTD1 | |
| SCHEMBL13005932 | 0.86 | L3MBTL3 (0.59) | L3MBTL3L3MBTL1GFERSMN1; SMN2MBTD1 | |
| SCHEMBL3761059 | 0.85 | L3MBTL3 (0.56) | HPGDL3MBTL3L3MBTL1GFERSMN1; SMN2 | |
| SCHEMBL3767816 | 0.83 | MEN1 (0.58) | GFERSMN1; SMN2ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| WO-2007016496-A2 | DIPIPERAZINYL KETONES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | GAA 2143/4885HPGD 377/4885L3MBTL3 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.